BioXcel Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 26.79 million compared to USD 52.8 million a year ago. Basic loss per share from continuing operations was USD 0.87 compared to USD 1.84 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.86 USD | +0.54% | -10.14% | -36.95% |
09/05 | BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
09/05 | Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.95% | 69.81M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- BTAI Stock
- News BioXcel Therapeutics, Inc.
- BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024